Cipher Capital’s Amicus Therapeutics FOLD Stock Holding History

Cipher Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,162	Closed	-$229K	–	495
2023 Q4	$229K	Buy	+16,162	New	+$184K	0.07%	399

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cipher Capital's FOLD Position: Q1 2024 in Review

Cipher Capital sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 16,162 shares — an estimated $229K sold.

Cipher Capital first reported a position in FOLD in Q4 2023 and held it in 1 quarter. The position peaked at $229K in Q4 2023. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

Cipher Capital reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
Cipher Capital sold 16,162 Amicus Therapeutics shares in Q1 2024, an estimated $229K.
Cipher Capital first reported a position in Amicus Therapeutics in Q4 2023 and held it in 1 quarter.
Cipher Capital's Amicus Therapeutics position peaked at $229K in Q4 2023.
254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.